Chunjing Wu

Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma

Lynn G. Feun, Yingying Li, Chunjing Wu et al. · Cancer · 2019 · 160 citations · Full text

Medicine, Oncology, Pharmacology +17

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer

Chunjing Wu, Medhi Wangpaichitr, Lynn G. Feun et al. · Molecular Cancer · 2005 · 127 citations · Full text

Medicine, Molecular Biology, Oncology +17

Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer

Medhi Wangpaichitr, Chunjing Wu, Ying Ying Li et al. · Oncotarget · 2017 · 105 citations · Full text

Medicine, Oncology, Pharmacology +16

The Relationship of Thioredoxin-1 and Cisplatin Resistance: Its Impact on ROS and Oxidative Metabolism in Lung Cancer Cells

Medhi Wangpaichitr, Elizabeth J. Sullivan, George Theodoropoulos et al. · Molecular Cancer Therapeutics · 2012 · 101 citations · Full text

Medicine, Cancer Biology, Oncology +17

Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins

Medhi Wangpaichitr, Chunjing Wu, Min You et al. · European Journal of Pharmacology · 2008 · 74 citations · Full text

Medicine, Molecular Biology, Oncology +13